title: Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism.
abstract: BACKGROUND
  The relationship between ischemia-modified albumin (IMA) and thyroid dysfunction remains uncertain. This study aimed to investigate the influence of overt hypothyroidism (Oho), overt hyperthyroidism (Ohe), and their treatments on serum IMA levels.
  
  
  METHODS
  A total of 35 untreated patients with Ohe, 35 untreated patients with Oho, and 35 control subjects were enrolled in the study. C-reactive protein (CRP), homocysteine (Hcy), IMA, and lipid profiles were measured and evaluated before and after treatment.
  
  
  RESULTS
  CRP, Hcy, and IMA levels and lipid profiles were higher in patients with Oho than in euthyroid or Ohe subjects (p<0.05). Basal IMA levels were reduced after treatments in all patients (p<0.05). In Ohe patients, serum IMA levels were positively correlated with free triiodothyronine (r=0.424, p=0.011) and free thyroxine (r=0.567, p<0.001) levels. In Oho patients, serum IMA levels were inversely correlated with free triiodothyronine (r=-0.555, p=0.001) and free thyroxine (r=-0.457, p=0.006) but positively correlated with anti-thyroid peroxidase antibody, C-reactive protein, and homocysteine levels (p<0.05). Linear regression analyses showed that free triiodothyronine was the most important factor affecting serum IMA levels in Ohe (β=0.694, p=0.019) and in Oho (β=-0.512, p=0.025).
  
  
  CONCLUSIONS
  IMA levels are increased in patients with thyroid dysfunction, particularly in overt hypothyroidism. Thyroid dysfunction has a significant impact on the oxidative stress status.
authors.affiliation: Department of Endocrinology and Metabolism, Affiliated Hospital of Guilin Medical College, No. 15 Lequn Road, Guilin 541001, China. mashaogang@163.com
authors.forename: Shao-gang
authors.initials: SG
authors.lastname: Ma
authors.forename: Liu-xue
authors.initials: LX
authors.lastname: Yang
authors.forename: Feng
authors.initials: F
authors.lastname: Bai
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Bing
authors.initials: B
authors.lastname: Hong
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006710:Homocysteine / Q000097:blood; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000628:therapy; D007037:Hypothyroidism / Q000097:blood* / Q000628:therapy; D007453:Iodide Peroxidase / Q000276:immunology; D008297:Male; D008713:Methimazole / Q000627:therapeutic use; D008875:Middle Aged; D018384:Oxidative Stress; D012709:Serum Albumin; D000075462:Serum Albumin, Human; D013974:Thyroxine / Q000097:blood / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D001323:Autoantibodies; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D012709:Serum Albumin; D014280:Triglycerides; C006606:anti-thyroglobulin; C561522:ischemia-modified albumin; D014284:Triiodothyronine; D006710:Homocysteine; D008713:Methimazole; D002097:C-Reactive Protein; D007453:Iodide Peroxidase; D013974:Thyroxine; D000075462:Serum Albumin, Human